Type B Aortic Dissection Quality Control Platform (NCT07745309) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Type B Aortic Dissection Quality Control Platform
2,375 participantsStarted 2026-08
Plain-language summary
This study aims to establish a multicenter, prospective, observational registry database for type B aortic dissection based on approximately 60 regional sentinel hospitals across China. It develops a digital intelligent management system, formulates quality control indicators and data collection standards for type B aortic dissection, and optimizes the data quality control and evaluation system to realize comprehensive evaluation covering the entire diagnosis and treatment process and long-term prognosis. Artificial intelligence algorithms are adopted to construct a risk prediction model for adverse events, and auxiliary decision-making software is developed to identify potential risks of adverse events in a timely manner and establish an early warning system, ultimately reducing the in-hospital complication and mortality rates.
Relying on the National Quality Control Platform for Peripheral Vascular Intervention, this study further builds a national quality control platform for type B aortic dissection covering more than 5,000 hospitals nationwide by establishing a three-level quality control system. By integrating health administrative data, quality control data, electronic medical record data and clinical research data, a high-quality, multi-dimensional national quality control platform is constructed to support the sustainable development of quality control work. In addition, a clinical research collaboration network will be established to conduct in-depth evaluation of the national diagnosis and treatment patterns and outcomes of type B aortic dissection. Regular national training and assessment programs will be organized to improve the overall diagnosis and treatment capacity of medical institutions at all levels and reduce regional and institutional disparities in the quality of clinical care for the disease.
Who can participate
Age range
18 Years – 80 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
. Aged between 18 and 80 years (inclusive);
. Definite diagnosis of Stanford type B aortic dissection confirmed by three-dimensional CTA reconstruction;
. Underwent TEVAR, including standalone TEVAR and hybrid procedures (only non-thoracotomy hybrid procedures);
. Patients and their families signed informed consent and agreed to complete the 2-year full follow-up.
Exclusion criteria
. Presence of severe comorbidities or other diseases (e.g., severe chronic obstructive pulmonary disease, malignant tumors, dementia) or any physical condition that may affect patient compliance with this study;
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Number of major adverse events
Timeframe: From surgery completion to 30 days after surgery completion
. A previous history of thoracic aortic surgery (including TEVAR, hybrid surgery, and open surgery);
. Congenital aortic malformations;
. Requiring concurrent intervention for cardiac or aortic sinus root lesions, or cardiac diseases that would alter the postoperative medication regimen;
. Pregnant or breastfeeding women;
. Complicated with Stanford type A intramural hematoma, supra-aortic vessel occlusion, or refusal of relevant repair;
. A history of stroke or acute myocardial infarction within 30 days prior to surgery;
. Receipt of any major surgical or interventional procedures within 30 days prior to surgery;